Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company dedicated to developing innovative multimodal viral immunotherapies to combat cancer, announced today the appointment of Bali Pulendran, Ph.D., to its Research Advisory Board (RAB). Dr. Pulendran, a globally renowned expert in systems immunology and vaccinology, is celebrated for his groundbreaking use of systems approaches to decode human immune responses. His expertise will bolster Candel’s efforts as it advances its lead viral immunotherapy candidate, CAN-2409, addressing multiple solid tumor types, along with CAN-3110 for recurrent high-grade glioma.
“I’m honored to join Candel’s Research Advisory Board during this pivotal stage for the Company,” stated Dr. Pulendran. “Candel’s innovative viral immunotherapy platform presents a promising strategy to activate the immune system against cancer. I look forward to contributing my knowledge in systems immunology and immune response mechanisms to help advance therapies that hold great potential to benefit cancer patients across various indications.”
Dr. Pulendran serves as the Violetta L. Horton Professor at Stanford University School of Medicine and is the Director of the Institute for Immunity, Transplantation and Infection at Stanford University. Additionally, he is a Fellow at ChEM-H (Chemistry, Engineering and Medicine for Human Health). Dr. Pulendran earned his Ph.D. under Sir Gustav Nossal at the Walter & Eliza Hall Institute. Among his many achievements, he has made pivotal contributions to human immunology and vaccinology, including uncovering the functional complexity of dendritic cell subtypes and the role of microbial stimuli in programming dendritic cells to regulate immune responses. His influential work has been featured in esteemed journals like Nature, Science, Cell, Nature Medicine, and Nature Immunology. He is also listed among Thomson Reuters’ Highly Cited Researchers, recognizing the top 1% of researchers worldwide based on citation impact.
Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of Candel Therapeutics, shared his enthusiasm for the new advisory board member. “We are thrilled to welcome Dr. Pulendran to our Research Advisory Board. His pioneering work in systems immunology and his deep expertise in how the immune system interacts with various stimuli align perfectly with our mission. His insights will be instrumental as we continue to push CAN-2409 forward for various solid tumors and advance CAN-3110 in recurrent high-grade glioma. Our goal remains clear—developing vital and potentially life-saving therapies for patients in need.”
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biopharmaceutical company focused on delivering innovative off-the-shelf, multimodal viral immunotherapies. These therapies elicit individualized and systemic anti-tumor immune responses, providing novel solutions for cancer treatment. The company has developed two clinical-stage platforms built around genetically modified viral gene constructs, leveraging adenovirus and herpes simplex virus (HSV) technologies. Their lead candidate, CAN-2409, originates from the adenovirus platform and is designed to address a variety of solid tumor indications.
For more information please visit www.candeltx.com
The post Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board appeared first on PRISM MarketView.
